EuroCetus B.V. has received approval in Denmark to marketCardioxane, an adjunct therapy for use against cardiac sideeffects induced by anthracycline chemotherapeutics, thecompany said Tuesday. This is the second European approval,following Italian approval in February.
Anthracycline-induced cardiotoxicity is relatively common.Doxorubicin and epirubicin, the most commonly prescribedanthracyclines, are widely used against cancers. As many as2,000 patients receive anthracycline treatment in Denmarkeach year, including about 1,000 breast cancer patients,according to EuroCetus.
EuroCetus, based in Amsterdam, the Netherlands, is a unit ofChiron Corp. of Emeryville, Calif. Chiron acquired Cadioxane inits acquisition of Cetus Corp. Chiron shares (NASDAQ:CHIR)closed at $51, up $1.13.
(c) 1997 American Health Consultants. All rights reserved.